Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer

Reuters2025-07-01

<a href="https://laohu8.com/S/VSTM">Verastem</a> Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer

Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630352590) on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2548017298?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548017298","market":"fut","top_or_hot":-1,"title":"Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630352590) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-01 04:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630352590) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLNfW37:1","article_id":"2548017298","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548017298","pubTimestamp":1751313745,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"Verastem Oncology获得FDA批准Avutometinib联合Defactinib治疗KRAS突变低级别浆液性卵巢癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9},"content_text":"Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib in KRAS-Mutated Low-Grade Serous Ovarian Cancer\n    \n\n        Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250630352590) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548017298","isCrawlerRequest":true}